<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857999</url>
  </required_header>
  <id_info>
    <org_study_id>INCOR 2993/07/008</org_study_id>
    <nct_id>NCT01857999</nct_id>
  </id_info>
  <brief_title>Losartan in Decompensated Heart Failure</brief_title>
  <official_title>Short-term add-on Therapy With Angiotensin Receptor Blocker for End-stage Inotrope-dependent Heart Failure Patients: B-type Natriuretic Peptide Reduction in a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InCor Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting
      enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients
      has been demonstrated to be beneficial. However, the dual inhibition has not been studied
      during heart failure decompensation or even when low cardiac output is present.

      The objective of this study was to assess the effects of add-on therapy with angiotensin
      receptor blocker on plasma B-type natriuretic peptide levels and hemodynamic measurements in
      heart failure patients with low cardiac output during hospitalization for decompensation.

      This was a randomized, double-blind, placebo-controlled clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inclusion criteria were hospitalization for decompensated heart failure defined by
      worsening of symptoms until fatigue or dyspnea at rest, low cardiac output defined by the
      clinical-hemodynamic profile, dobutamine dependence, and ejection fraction &lt; 0.45,
      spontaneous breathing and receiving angiotensin-converting enzyme inhibitors. The patients
      could have jugular ingurgitation, lower limbs edema, ascites and rales. Dobutamine dependence
      was defined by infusion for more than 15 days or an unsuccessful attempt of withdrawal.

      The exclusion criteria were serum creatinine &gt; 3.0 mg/dL, serum potassium &gt; 6.0 mEq/L,
      systolic blood pressure &lt; 70 mm Hg, aortic stenosis, and acute coronary syndrome in the
      previous 2 months. The patients were randomly assigned by permuted block of 4, stratified by
      sex, to losartan or placebo.

      The endpoints were change in B-type natriuretic peptide levels, cardiac index, pulmonary
      wedge capillary pressure, systemic vascular resistance, and successful withdrawal of
      dobutamine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>B-type natriuretic peptide</measure>
    <time_frame>7 days</time_frame>
    <description>Serum B-type natriuretic peptide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful withdrawal from dobutamine</measure>
    <time_frame>7 days</time_frame>
    <description>Successful withdrawal from dobutamine with clinical stability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening renal function</measure>
    <time_frame>7 days</time_frame>
    <description>Increase &gt; 0.3 mg/dL in serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperkalemia</measure>
    <time_frame>7 days</time_frame>
    <description>Serum potassium &gt; 5.5 mEq/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>7 days</time_frame>
    <description>Systolic blood pressure &lt; 80 mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Low Cardiac Output</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 50 mg bid orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 pill bid orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hospitalization for decompensated heart failure

          -  dobutamine dependence

          -  ejection fraction &lt; 0.45

          -  taking angiotensin-converting enzyme inhibitor

        Exclusion Criteria:

          -  serum creatinine &gt; 3.0 mg/dL

          -  serum potassium &gt; 6.0 mEq/L

          -  systolic blood pressure &lt; 70 mm Hg

          -  aortic stenosis

          -  acute coronary syndrome in the previous 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio P Barretto, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Heart Institute (InCor), University of S찾o Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cotox처 Hospital, Heart Institute (InCor), University of S찾o Paulo</name>
      <address>
        <city>S찾o Paulo</city>
        <state>SP</state>
        <zip>05021-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>InCor Heart Institute</investigator_affiliation>
    <investigator_full_name>Marcelo Eidi Ochiai</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Renin-aldosterone system</keyword>
  <keyword>Hemodynamic</keyword>
  <keyword>Low cardiac output</keyword>
  <keyword>Vasodilation</keyword>
  <keyword>Natriuretic peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiac Output, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

